News & Press Releases

Mintz is advising the placement agents in connection with the $350 million private placement that is expected to close immediately prior to the completion of the merger transaction between Obsidian Therapeutics, Inc. and Galera Therapeutics, Inc.

Mintz advised the placement agent in connection with ImageneBio’s $30 million private placement of pre-funded warrants.

Steven Shparber, Co-chair of Mintz’s Digital Infrastructure Practice, recently spoke with Data Center Knowledge about the growing use of behind-the-meter power by data center operators as they face grid delays and rising AI-driven demand.

Michelle Capezza was quoted in a Fiduciary News article examining whether increasingly complex investment options, such as private equity and other alternatives, belong in participant directed 401(k) plans. The article explores this issue against the backdrop of proposed Department of Labor regulations that continue to emphasize a process based fiduciary standard.

Michelle Capezza was quoted in a Fiduciary News article examining the fiduciary risks and operational challenges created by the SECURE 2.0 Act Saver’s Match program, particularly as plan sponsors navigate new responsibilities without final regulatory guidance.

Mintz advised the placement agent in connection with SCYNEXIS’ up to $92.2 million private placement. The private placement included upfront gross proceeds of approximately $40.0 million in common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants, and up to an additional $52.2 million in gross proceeds if the common warrants are exercised for cash, subject to stockholder approval to increase the number of authorized shares of common stock.